Drug Interactions You Must Know for MRCP Part 1
- Crack Medicine
- Jan 18
- 4 min read
TL;DR:
In MRCP Part 1, drug interactions are tested as clinical consequences, not lists to memorise. Focus on enzyme induction/inhibition, QT prolongation, bleeding risk, and renal toxicity patterns that explain adverse outcomes. This guide outlines the examinable scope, high-yield interactions, classic traps, and a practical way to revise them efficiently.
Why this matters
Drug interactions are a reliable source of marks in MRCP Part 1 because they integrate pharmacology with real-world clinical reasoning. The exam rarely asks you to recall obscure metabolic pathways; instead, it presents a patient on multiple medications who deteriorates, bleeds, becomes hypotensive, or develops arrhythmia. Your task is to recognise why.
From a revision perspective, interactions are high-yield because the same principles recur across specialties—cardiology, infectious diseases, neurology, psychiatry, and endocrinology. If you master a small set of mechanisms, you can answer a wide range of questions. This article supports the parent hub on MRCP Part 1 preparation and complements question-based learning from a focused QBank.
Scope of drug interactions in MRCP Part 1
The exam tests interactions through clinical consequences, not theoretical lists. Expect interactions to appear in:
Short clinical vignettes with a recent medication change
Adverse effects after starting antibiotics or antifungals
Bleeding or thrombosis in patients on antithrombotics
Arrhythmias or syncope linked to QT prolongation
Loss of efficacy after enzyme induction
You are not expected to know detailed CYP isoenzyme numbers. You are expected to know which drugs broadly induce, inhibit, or compound toxicity.
High-yield drug interactions you must know (exam-focused)
Below is a numbered, high-yield list that covers the interactions most frequently tested in MRCP-style questions.
Warfarin + antibiotics (e.g. macrolides, metronidazole)→ ↑ INR and bleeding due to reduced metabolism and gut flora suppression.
Warfarin + enzyme inducers (rifampicin, carbamazepine, phenytoin)→ ↓ INR and thrombosis risk from increased hepatic metabolism.
ACE inhibitors / ARBs + NSAIDs + diuretics (the “triple whammy”)→ Acute kidney injury from combined afferent and efferent arteriolar effects.
Macrolides or fluoroquinolones + QT-prolonging drugs→ Torsades de pointes risk, especially with antipsychotics or TCAs.
Statins + macrolides (especially clarithromycin)→ Myopathy and rhabdomyolysis due to inhibited statin metabolism.
Nitrates + phosphodiesterase-5 inhibitors (e.g. sildenafil)→ Profound hypotension and syncope.
SSRIs + NSAIDs or antiplatelets→ Increased gastrointestinal bleeding risk (platelet dysfunction + mucosal injury).
Lithium + ACE inhibitors / thiazides / NSAIDs→ Lithium toxicity due to reduced renal clearance.
Oral contraceptive pill + enzyme inducers→ Reduced contraceptive efficacy and unintended pregnancy.
Digoxin + amiodarone or verapamil→ Digoxin toxicity from reduced clearance and P-glycoprotein inhibition.
These interactions recur across papers because they test mechanism-based reasoning, not recall.
The 5 most tested interaction mechanisms
Understanding these mechanisms allows you to predict interactions in unseen questions.
1. Enzyme inhibition
Rapid onset (days). Leads to toxicity of the affected drug.Classic offenders: macrolides, azoles, amiodarone.
2. Enzyme induction
Delayed onset (1–2 weeks). Leads to loss of efficacy. Classic offenders: rifampicin, carbamazepine, phenytoin.
3. Additive pharmacodynamic effects
No metabolism involved—effects simply add up. Example: nitrates + sildenafil → hypotension.
4. Renal haemodynamic interactions
Affect glomerular perfusion and clearance. Example: ACE inhibitor + NSAID → AKI.
5. QT prolongation synergy
Multiple drugs prolonging repolarisation → arrhythmia risk. Exam clue: syncope, palpitations, polymorphic VT.
Mini-case (MRCP-style)
A 72-year-old man with atrial fibrillation is stable on warfarin. He develops pneumonia and is started on clarithromycin. Three days later, he presents with epistaxis and haematuria.
What is the most likely mechanism?
Answer: Enzyme inhibition leading to increased warfarin effect.
Explanation: Clarithromycin inhibits hepatic metabolism of warfarin and reduces vitamin-K-producing gut flora, causing a rapid rise in INR. In MRCP Part 1, bleeding shortly after starting an antibiotic should immediately prompt this association.
Common exam traps (and how to avoid them)
Trap 1: Assuming all antibiotics reduce warfarin effect Fix: Most increase INR; rifampicin is the key exception.
Trap 2: Missing delayed interactions Fix: Enzyme induction takes time—think weeks, not days.
Trap 3: Ignoring renal function in elderly patients Fix: Many toxicity questions hinge on reduced clearance.
Trap 4: Over-focusing on rare CYP facts Fix: Stick to clinical outcomes: bleed, clot, arrhythmia, AKI.
Trap 5: Forgetting additive effects Fix: If two drugs share a side effect, expect synergy.
Practical study checklist for drug interactions
Use this checklist during revision and question practice:
□ Can I explain the interaction mechanism in one sentence?
□ Does it cause toxicity or loss of efficacy?
□ Is the onset rapid (inhibition) or delayed (induction)?
□ Would renal or hepatic impairment worsen it?
□ Have I seen this tested in my Free MRCP MCQs or mock exams?
A targeted mock test review often reveals that the same interaction is tested repeatedly with different clinical windows.
How this fits into your MRCP Part 1 plan
Drug interactions should be revised after core pharmacology but before full-length mocks. They work best with question-based learning: attempt MCQs, analyse the mechanism, then consolidate with brief notes. For structured coverage, see the MRCP Part 1 overview hub and integrate interactions into your broader systems-based revision.
Suggested sibling reading:
Common pharmacology exam traps (blog)
How to approach adverse drug reaction questions in MRCP Part 1 (blog)
FAQs
Do I need to memorise all CYP enzymes for MRCP Part 1?No. The exam focuses on predictable clinical consequences, not enzyme numbers. Broad inhibitor vs inducer knowledge is sufficient.
Are drug interactions asked directly or via cases? Almost always via short clinical vignettes with deterioration after a medication change.
Which interactions are most commonly tested? Warfarin interactions, QT prolongation combinations, lithium toxicity, and AKI-related combinations are particularly high-yield.
How should I revise interactions efficiently? Use MCQs first, then summarise mechanisms in brief notes. Re-test during mocks to reinforce recall.
Are rare interactions worth learning? Only if they illustrate a common mechanism. Prioritise patterns over exceptions.
Ready to start?
If you want to see how these interactions are tested in real exam-style questions, practise with our Free MRCP MCQs and consolidate your timing with a mock test. Keep this page bookmarked as a rapid-revision checklist during your final MRCP Part 1 run-up.
Sources
MRCP(UK) Examination Regulations and Guidance
British National Formulary (BNF)
Katzung BG. Basic & Clinical Pharmacology
Comments